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Eukaryotic cells degrade proteins through two systems, 
the  ubiquitin-proteasome  system,  and  autophagy, 
whereby cytoplasmic components become enclosed in a 
double membrane to form a compartment known as the 
autophagosome  and  are  delivered  to  the  lysosome  for 
degradation. Constitutive, basal autophagy occurs under 
nutrient rich conditions and serves as a quality control 
mechanism for both proteins and organelles, to protect 
the  cell  from  the  consequences  of  aggregated  proteins 
and  damaged  organelles  that  could  cause  the 
development  of  disease:  failure  of  this  system  is 
implicated  in  the  development  of,  for  example, 
neurodegenerative disease and cancer. Autophagy is also 
induced in response to starvation in order to generate 
nutrients  and  energy  through  the  degradation  of 
macromolecules and organelles [1,2].
Autophagy and disease
Research during the last decade has made it increasingly 
clear that autophagy plays important roles in most of the 
major  human  diseases  as  well  as  in  infection  and 
immunity  [1,2],  with  increasing  evidence  for  selective 
autophagy  of  protein  aggregates,  organelles  and 
pathogens  [3].  Autophagy  may,  depending  on  the 
circumstances, either inhibit or promote tumor growth. 
Thus it may contribute to genomic stability by clearing 
cells of damaged organelles and protein aggregates that 
produce  reactive  oxygen  species  resulting  in  DNA 
damage; or on the other hand, it may help tumor cells 
survive  stress  conditions  like  hypoxia  and  nutrient 
deprivation  [4].  Neurodegenerative  disorders  such  as 
Alzheimer’s,  Huntington’s  and  Parkinson’s  disease  are 
characterized by the deposition of intra- and extracellular 
proteins  aggregates  that  are  not  degraded  by 
proteasomes.  Thus,  activation  of  autophagy  is  often 
observed in protein aggregation diseases and autophagy 
deficiency leads to neurodegeneration in mice and fruit 
flies.  The  life  span  of  organisms  as  diverse  as 
Caenorhabditis  elegans  and  Drosophila  and  even  mice 
can  be  significantly  increased  by  boosting  autophagy. 
Efficient  autophagy  may  thus  protect  against 
neurodegeneration and increase longevity [1,2].
Because  of  the  involvement  of  autophagy  in  many 
disease  conditions  there  is  great  interest  in  identifying 
drugs  that  can  be  used  to  manipulate  autophagy  for 
therapeutic  purposes.  An  important  step  towards  this 
goal is to establish assays and screening systems where 
the  autophagic  flux  can  be  measured  rapidly  and 
precisely in response to drugs. Autophagic flux refers to 
the  complete  process  of  autophagy  (Figure  1),  which 
begins with the formation of a crescent-shaped double 
membrane,  the  phagophore,  which  expands  around  a 
portion  of  cytoplasm  and  fuses  to  form  the 
autophagosome. The mature autophagosome then either 
fuses  directly  with  a  lysosome  to  generate  an 
autolysosome, or fuses first with a late endosome to form 
an amphisome, which then fuses with the lysosome to 
give an autolysosome. In the autolysosome, the cargo is 
degraded.
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It is important to distinguish effects on lysosomal activity 
from effects on autophagosome formation. This problem 
has not previously been properly addressed in screening 
assays used to identify compounds modulating autophagy. 
The assay described by Hundeshagen and colleagues [5], 
by  the  ingenious  use  of  tandem  fluorescent  tags  with 
differential pH sensitivity, allows this discrimination. The 
authors use this assay successfully in a secondary screen 
to identify cardiac glycosides as modulators of autophagy.
Most  assays  for  autophagy  modulators  use  the 
autophagy marker protein LC3 as readout for autophagic 
activity. LC3 is a mammalian homolog of the yeast ATG8 
protein, a ubiquitin-like protein that becomes lipidated 
and  tightly  associated  with  the  autophagosomal 
membranes.  LC3  is  also  important  in  the  process  of 
selective  autophagy,  whereby  intracellular  components 
such as protein aggregates, organelles and pathogens are 
removed  [3].  Selective  autophagy  is  mediated  by 
autophagic cargo receptors such as p62, NBR1, NDP52 
and NIX, which contain an LC3-interacting region (LIR) 
and can therefore bind directly to LC3 [3]. LC3 proteins 
are specifically cleaved at their carboxyl termini to form 
LC3-I,  which  has  an  exposed  carboxy-terminal  glycine 
that is conjugated to phosphatidylethanolamine to form 
LC3-II,  which  is  tightly  bound  to  the  autophagosomal 
membranes and serves as an autophagic marker protein.
The  most  popular  of  the  assays  using  LC3  are 
microscopy-based green fluorescent protein (GFP)-LC3 
puncta formation assays and western blots of LC3-I and 
LC3-II forms [6]. Shvets et al. more recently pioneered 
the  use  of  flow  cytometry  to  quantify  the  turnover  of 
GFP-LC3 as an assay to measure autophagic activity in 
living mammalian cells [7].
Hundeshagen and colleagues [5] used GFP-LC3B in an 
initial  screen  by  flow  cytometry  to  quantify  auto-
phagosome formation in response to a library of 1,120 
Food  and  Drug  Administration  approved  compounds. 
The assay uses the human breast cancer cell line MCF-7 
stably  expressing  GFP-LC3B  to  quantify  autolysosome 
formation  measuring  GFP  fluorescence  intensity  in 
96-well plates, and identified 38 compounds as potential 
activators and 36 as inhibitors of autophagy. Among the 
activators  were  several  cardiac  glycosides,  including 
digoxin, strophanthidin and digoxigenin, and in the next 
step,  these  compounds  were  screened  using  a  tandem 
fusion of the red, acid-insensitive mCherry and the acid-
sensitive  GFP  to  measure  formation  of  autolysosomes 
and their degradation by flow cytometry in a large cell 
population  (Figure  2).  Because  of  the  low  pH  of  the 
autolysosome,  the  green  fluorescence  from  the  acid-
sensitive  GFP  is  lost  on  fusion  of  the  autophagosome 
with  the  lysosome,  but  the  red  fluorescence  from  the 
acid-insensitive mCherry is not lost until the proteins are 
Figure 1. The autophagic and endolysosomal pathways intersect and interconnect. Schematic drawing showing the autophagy process with 
phagophore and autophagosome formation followed by fusion of autophagosomes either directly to lysosomes to form autophagosomes, or to 
late endosomes to give amphisomes that subsequently fuse with lysosomes. Lipidated LC3-II, used as a marker for autophagy, is tightly associated 
with the autophagosomes. Note that Rab7, used as a marker of the endolysosomal pathway, is involved in both the autophagic and endolysosomal 
pathways.
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distinguish  autophagosomes  from  autolysosomes  has 
been described before [8,9], but this is the first report of 
its use for flow cytometry to monitor distinct steps in the 
autophagic pathway.
The significance of cardiac glycosides, and some 
provisos
A  general  problem  when  attempting  to  measure  auto-
phagic flux is the interconnection between the endocytic 
and  autophagosomal  pathways  (see  Figure  1),  which 
makes it difficult to ensure that the observed effects are 
on autophagic flux and not the endolysosomal pathway. 
Compounds  affecting  late  steps  of  the  autophagic 
pathway may also interfere with the endocytic pathway. 
To address this, Hundeshagen et al. [5]used GFP-Rab7 as 
a  marker  of  endolysosomal  activity.  Rab7  is  associated 
with late endosomes, lysosomes and auto  lysosomes and 
is required for fusion of autophagosomes to lysosomes 
(see Figure 1) and is therefore not a specific indicator of 
endolysosomal flux. However, since the authors [5] monitor 
the fluorescence levels of GFP-Rab7 along with the double 
tagged LC3, the strategy seems reasonable and can give 
valuable information on effects on endolysosomal activity.
Using  the  double  tag  LC3B  and  the  GFP-Rab7 
degradation  assays,  Hundeshagen  et  al.  [5]  showed 
digoxin  to  be  the  most  potent  autophagy  stimulator. 
Cardiac glycosides are used in treatment of heart failure 
and arrhythmia. These drugs increase the level of calcium 
by  inhibiting  the  Na+/K+-ATPase,  and  thereby  increase 
cardiac  contractile  force.  It  is  known  that  increases  in 
intracellular calcium induce autophagy, so it is perhaps 
not surprising that cardiac glycosides activate autophagy. 
Cardiac  glycosides  have  been  suggested  for  cancer 
therapy, and their stimulatory effect on autophagy may 
be important in this context.
There is one further proviso about screening strategy. 
Hundeshagen  et  al.  [5]  used  GFP-LC3  for  the  initial 
screen  and  then  employed  mCherry-GFP-LC3  in  a 
secondary screening, so it is not clear what the outcome 
would have been if the authors had used mCherry-GFP-
LC3  in  the  primary  screen.  The  importance  of  the 
strategy chosen for the primary screen is emphasized by 
results  from  another  group  [10],  who  screened  a 
collection  of  3,584  chemicals,  including  the  chemical 
library Hundeshagen et al. [5] used, and in the same cell 
line, without identifying the same autophagy modulators. 
The  difference  was  that  Balgi  et  al.  [10]  used  an 
automated  microscopy  screen  based  on  the  GFP-LC3 
puncta  formation  assay.  In  this  screen  perhexiline, 
niclosamide, amiodarone and rottlerin were identified as 
autophagy modulators [10]. Considering these different 
results, and the caveats and shortcomings that different 
assays have, it seems necessary to use a combination of 
different assays to perform exhaustive screens for small 
molecule autophagic modulators.
Figure 2. Tracking different stages of autophagy with double-tagged LC3B. A tandem fusion of mCherry and GFP is fused to LC3B (one of the 
several members of the mammalian LC3 family) to make a pH-sensitive sensor that is used to monitor autophagy in live cells. The GFP tag is acid-
sensitive while the mCherry tag is acid-insensitive. The double tagged LC3 can be used to label autophagosomes, amphisomes and autolysosomes. 
In autophagosomes both tags emit fluorescent light resulting in a yellow fluorescence. However, fusion of autophagosomes to late endosomes or 
lysosomes results in acidic amphisomes or autolysosomes where the green fluorescence from GFP is lost. Subsequently, the red fluorescence from 
mCherry is lost when the double tagged protein is degraded.
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is clearly a step forward in quantitative cell population 
based  monitoring  of  distinct  steps  of  the  autophagy 
pathway  in  the  screening  for  autophagy  modulators. 
Further  development  and  refinement  of  autophagy 
screening protocols from this and other groups are to be 
expected.
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